cetuximab beta

Cetuximab beta is a **recombinant monoclonal antibody** targeting the **epidermal growth factor receptor (EGFR)**. Developed in China, cetuximab beta is a second-generation EGFR inhibitor, produced using a proprietary protein expression technique that minimizes immunogenic glycosylation, reducing the risk of hypersensitivity reactions. It is indicated in combination with the FOLFIRI regimen as a first-line treatment for **RAS/BRAF wild-type metastatic colorectal cancer (mCRC)**. The mechanism of action involves binding to EGFR, blocking receptor phosphorylation and activation of downstream signaling, which leads to inhibition of tumor cell growth, induction of apoptosis, decreased VEGF production, and enhanced cytotoxicity with chemotherapy[2].

Brand names

Enlituo

Other names

cetuximab betacetuxima-βcetuximab-beta